Eli Lilly Acquires AtaiBeckley, Boosting Psychedelic Drug Market

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals a significant 'buy signal' for the market of psychedelic drugs aimed at treating mental health conditions, marking Big Pharma's growing acceptance of these previously stigmatized medications.

19 Jul, 14:45 — 19 Jul, 14:45

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual13d ago

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.

Read full article →

PERSPECTA

PERSPECTA

Eli Lilly Acquires AtaiBeckley, Boosting Psychedelic Drug Market

Sources

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Related Stories

Fishwife CEO Hires Candidate Based on Cold LinkedIn Outreach

QuickFlips Founder Turns Side Hustle into $4 Million Video Game Resale Business

DoorDash Pays Gig Workers to Load Delivery Robots, Highlighting Automation Shortcoming

Cheryl Patella Moves from Miami to Rural North Florida for Improved Lifestyle

PERSPECTA